Richard Pops

Alkermes Weighs Splitting Off Cancer Biz as Separate, Publicly Traded Company

Alkermes says separating cancer from its portfolio and pipeline of neuroscience products could put the company on a path to profitability. Meanwhile, the new cancer company would be an independent and publicly traded entity with a lead immunotherapy in pivotal testing for two types of cancer.

By Frank Vinluan

BioPharma, Pharma

Bouncing back from FDA rejection, Alkermes psychiatric drug wins approval

Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate the weight gain side effect common with mood disorder drugs, could have an advantage.

By Frank Vinluan

Health IT

Reducing Clinical and Staff Burnout with AI Automation

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.

By Dr. Michael Blackman, Chief Medical Officer at Greenway Health

Market Trends to Watch for Health Systems and Their Specialty Pharmacies

The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.

By Jake Gaffey, MBA, Chief Strategy Officer at Shields Health Solutions

Consumer / Employer

Health Executives on Digital Transformation in Healthcare

Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.

By MedCity News

Consumer / Employer

Health Executives on Digital Transformation in Healthcare

Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.

By MedCity News